31 completed, 7 unknown, 5 terminated, 2 active not recruiting. 46 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 46 | Completed 31, Unknown 7, Terminated 5, Active not recruiting 2, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Unknown 2 |
Follow Fluoxetine: new trials by email Literature Review of Fluoxetine trials Research Report on Fluoxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients Fluoxetine, Roflumilast, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Tanta University | 60 | 2025-03-01 | 2026-05-04 |
| Improving Outcomes in Depression in Primary Care in a Low Resource Setting Healthy Activity Program (HAP), Antidepressant medication (fluoxetine) - Depression, Depressive Disorder | Phase 3 | Active not recruiting | Harvard Medical School (HMS and HSDM) | 1500 | 2024-03-18 | 2026-05-22 |
| TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic Transcranial Direct Current Stimulation, Placebo-simulation of transcranial direct current stimulation, Fluoxetine Tablets - Major Depressive Disorder | Phase 2 / Phase 3 | Unknown | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | 172 | 2021-10-01 | 2021-06-04 |
| Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 600 | 2021-04-12 | 2023-01-31 |
| Fluoxetine vs CBT in Childhood Anxiety Disorders Fluoxetine, Cognitive Behavioral Therapy (CBT) - Anxiety Disorders | Phase 3 | Active not recruiting | Children's Hospital Los Angeles | 316 | 2021-02-10 | 2025-04-11 |
| Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms Spirulin Platensis, Budesonide Powder, Fluoxetine 20 MG - Covid19, SARS-Associated Coronavirus | Phase 3 | Unknown | Cardresearch | 7819 | 2021-01-19 | 2024-05-08 |
| The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children Fluoxetine, Placebo - Nocturnal Enuresis | Phase 3 | Unknown | Mansoura University | 100 | 2020-07-01 | 2020-12-19 |
| Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder Levomilnacipran ER, Fluoxetine, Placebo - Major Depressive Disorder | Phase 3 | Completed | Allergan | 501 | 2018-07-06 | 2022-03-25 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day - Depressive Disorder, Major | Phase 3 | Completed | H. Lundbeck A/S | 683 | 2016-05-18 | 2022-09-22 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day - Depressive Disorder, Major | Phase 3 | Completed | H. Lundbeck A/S | 784 | 2016-05-01 | 2020-08-19 |
| The Staged Treatment in Early Psychosis Study Support and Problem Solving Therapy, Cognitive Behavioural Case Management, Fluoxetine - Psychotic Disorders, Personality Disorders | Phase 3 | Completed | Orygen | 342 | 2016-04-01 | 2025-10-02 |
| Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? Fluoxetine, Combined oral contraceptives, Placebo 1 - Premenstrual Syndrome | Phase 3 | Unknown | Cairo University | 300 | 2015-10-01 | 2016-07-06 |
| Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome Combined oral contraceptives, Fluoxetine, Combined oral contraceptives placebo - Premenstrual Syndrome | Phase 3 | Unknown | Cairo University | 300 | 2015-07-01 | 2017-01-23 |
| Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder Placebo, Levomilnacipran, Fluoxetine - Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 552 | 2015-06-23 | 2020-09-07 |
| Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome Dienogest, Fluoxetine, Placebo - Premenstrual Syndrome | Phase 3 | Unknown | Cairo University | 210 | 2015-04-01 | 2020-12-01 |
| Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) Vilazodone, Placebo, Fluoxetine - Major Depressive Disorder | Phase 3 | Completed | Forest Laboratories | 473 | 2015-02-28 | 2019-10-01 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Efficacy of Fluoxetine - a Trial in Stroke Fluoxetine, Placebo - Stroke | Phase 3 | Completed | Karolinska Institutet | 1500 | 2014-10-20 | 2020-09-02 |
| A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing Fluoxetine - Major Depressive Disorder | Phase 3 | Completed | Eli Lilly and Company | 200 | 2013-05-01 | 2015-11-26 |
| A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing Fluoxetine, Placebo - Major Depressive Disorder | Phase 3 | Completed | Eli Lilly and Company | 513 | 2013-03-01 | 2015-05-12 |
Showing 20 of 46. Sign in to see all of them.
Depressive Disorder, Major (18) · Depression (13) · Anxiety Disorders (3) · COVID-19 (3) · Depressive Disorder (3) · Premenstrual Syndrome (3) · Autistic Disorder (2) · Depressive Disorder, Treatment-Resistant (2) · Tobacco Use Disorder (2) · Bipolar Disorder (1) · Cardiovascular Diseases (1) · Cerebral Hemorrhage (1) · Cerebrovascular Disorders (1) · Dementia (1) · Dysthymic Disorder (1)
Eli Lilly and Company (7) · Cairo University (3) · Forest Laboratories (2) · H. Lundbeck A/S (2) · National Institute of Mental Health (NIMH) (2) · Neuropharm (2) · University of Pittsburgh (2) · ANRS, Emerging Infectious Diseases (1) · Allergan (1) · AstraZeneca (1) · Boston University (1) · Butler Hospital (1) · Cardresearch (1) · Children's Hospital Los Angeles (1) · Duke University (1)
United States (24) · Canada (8) · Mexico (7) · France (6) · Germany (6) · Egypt (5) · Russia (5) · South Africa (5) · Poland (4) · Ukraine (4) · Hungary (3) · Serbia (3) · Argentina (2) · Australia (2) · Bulgaria (2)
Ahmed Abdelhalem (1) · Akbar Fotouhi, MD, PhD (1) · Alexander J. Kiss, Dr. (1) · Amy HY Cheung, Dr. (1) · Angel A Arauz, PhD (1) · Anne Marie Albano (1) · Anthony J. Levitt, Dr. (1) · Arash Etemadi, MD, PhD (1) · Behtash Saeidi, MD (1) · Bessel Van Der Kolk, MD (1) · Bonnie Spring, PhD (1) · Boris Birmaher, MD (1) · Bradley S. Peterson, MD (1) · Bruce Waslick (1)
PMID 25978741, PMID 38700708, PMID 10990547, PMID 11063978, PMID 11723286, PMID 12244081, PMID 12649628, PMID 12949224, PMID 14677403, PMID 15147306, PMID 15315995, PMID 15351385, PMID 15608541, PMID 15987799, PMID 16002441, PMID 16794566, PMID 17135984, PMID 17135985, PMID 17135986, PMID 17135987, PMID 17135988, PMID 17135989, PMID 17295567, PMID 17335320, PMID 17450048, PMID 17591596, PMID 17907854, PMID 17909125, PMID 18030084, PMID 18030086, PMID 18314433, PMID 18391133, PMID 19182688, PMID 19183470, PMID 19223438, PMID 19332318, PMID 19358791, PMID 19403329, PMID 19465880, PMID 19485586, PMID 19671217, PMID 19723787, PMID 19730273, PMID 19730274, PMID 19853048, PMID 19858762, PMID 19877976, PMID 19968380, PMID 20006865, PMID 20008943
2008 (3), R01DA023190 (1), R01MH053681 (1), R01MH053703 (1), R01MH055121 (1), R01MH058356 (1), R01MH058363 (1), R01MH058397 (1), R01MH069618 (1), R01MH069619 (1), R01MH121632 (1), U01MH061835 (1), U01MH105258 (1), U10MH066750 (1), U10MH066762 (1)